AMEDIUM SIGNALOPERATIONAL10-K

Agilent completed a significant organizational restructuring in November 2024, creating new business segments while reducing share buybacks by 63% and building cash reserves.

The company has moved beyond routine segment adjustments to a comprehensive "market-focused, customer-centric" reorganization that fundamentally reshapes how it operates across three redesigned business units. This represents a strategic pivot that investors should monitor closely, as management is clearly repositioning the company for different growth priorities and market dynamics.

Comparing 2025-12-22 vs 2024-12-20View on EDGAR →
FINANCIAL ANALYSIS

Agilent's financial position strengthened notably with cash increasing 34.6% to $1.8B and stockholders' equity growing 14.3% to $6.7B, while the company dramatically reduced share buybacks from $1.1B to $425M, signaling a shift toward cash preservation and potential reinvestment. Operating cash flow declined 11% to $1.6B and current liabilities increased 23.9%, but the overall picture shows a company building financial flexibility during a period of strategic transformation. The market value of non-affiliate holdings declined from $30.0B to $26.6B, reflecting either share price pressure or changes in ownership structure during this transition period.

FINANCIAL STATEMENT CHANGES
Share Buybacks
Cash Flow
-63%
$1.1B$425.0M

Buyback activity reduced 63% — capital being redeployed elsewhere or cash conservation underway.

Cash & Equivalents
Balance Sheet
+34.6%
$1.3B$1.8B

Cash position surged 34.6% — strong cash generation or capital raise providing significant financial cushion.

Current Liabilities
Balance Sheet
+23.9%
$1.9B$2.3B

Current liabilities rose 23.9% — increased short-term obligations, watch current ratio.

Current Assets
Balance Sheet
+16%
$4.0B$4.6B

Current assets grew 16% — improving short-term liquidity or inventory/receivables build.

Stockholders Equity
Balance Sheet
+14.3%
$5.9B$6.7B

Equity base grew 14.3% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Accounts Receivable
Balance Sheet
+12.3%
$1.3B$1.5B

Receivables grew 12.3% — monitor days sales outstanding for collection efficiency.

Operating Cash Flow
Cash Flow
-11%
$1.8B$1.6B

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

LANGUAGE CHANGES
NEW — 2025-12-22
PRIOR — 2024-12-20
ADDED
Ye s No The aggregate market value of the registrant's common equity held by non-affiliates as of April 30, 2025, was approximately $ 26.6 billion.
As of December 10, 2025 there were 283,498,871 outstanding shares of common stock, par value $0.01 per share.
In November 2024, we announced a change in our organizational structure to support our market-focused, customer-centric strategy.
Our former Diagnostics and Genomics segment combined with our liquid chromatography and liquid chromatography mass spectrometry instrument platforms to form our new Life Sciences and Diagnostics Markets segment.
Our chemistries and supplies, laboratory automation, and software and informatics divisions moved from our former Life Sciences and Applied Markets segment to our Agilent CrossLab segment.
+7 more — sign up free →
REMOVED
Ye s No The aggregate market value of the registrant's common equity held by non-affiliates as of April 30, 2024, was approximately $ 30.0 billion.
As of December 9, 2024 there were 285,595,302 outstanding shares of common stock, par value $0.01 per share.
In the first quarter of fiscal year 2024, we announced a change in our operating segments to move our cell analysis business from our life sciences and applied markets segment to our diagnostics and genomics operating segment in order to further strengthen growth opportunities for both organizations.
Following this reorganization, we continued to have three business segments comprised of life sciences and applied markets, diagnostics and genomics and Agilent CrossLab, each of which continues to comprise a reportable segment.
All historical financial segment information has been recast to conform to this new presentation in our consolidated financial statements and accompanying notes.
+7 more — sign up free →
MORE OPERATIONAL SIGNALS
HOFTHIGHHOFT completed a major divestiture of its Pulaski and Samuel Lawrence furniture ...
2026-04-17
CTRNHIGHCTRN underwent a dramatic operational turnaround with a complete repositioning f...
2026-04-15
ORBSHIGHORBS has undergone a complete business transformation from packaging and e-comme...
2026-04-15
BRFHHIGHBRFH completed a transformative acquisition of Arps Dairy in October 2025, drama...
2026-04-15
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →